Anticholinergic medication remains integral in the management of women with Overactive Bladder syndrome although there is increasing evidence to support a link with the impairment of cognitive function. This editorial will review the available evidence and discuss the management of patients in order to minimise anticholinergic burden with a particular focus on the elderly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906708 | PMC |
| http://dx.doi.org/10.1016/j.crwh.2019.e00164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Dementia is a growing global public health challenge. Previous meta-analyses have found that systemic medications may modulate dementia risk. We aimed to provide an overview of this evidence.
View Article and Find Full Text PDFPurpose: To evaluate dynamic changes in ciliary parameters and Implantable Collamer Lens V4C (ICL) (STAAR Surgical) haptic position using mydriatic and miotic agents and their effects on the central and peripheral vault.
Methods: This study involved 80 eyes from 40 consecutive patients (mean age: 28.05 years; range: 19 to 42 years) examined 3 months after ICL implantation.
Developing Topics.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: Studies that report an association between anticholinergic medications and dementia often suffer from confounding by indication and rarely consider gender effects. We estimated the association between recurrent prescriptions for anticholinergic overactive bladder (OAB) medications and incident dementia, separately in men and women.
Method: We studied patients aged ≥50 years first prescribed an anticholinergic OAB drug (e.
Background: Over half of ambulatory older adults are prescribed at least one anticholinergic medication to address a myriad of conditions, including incontinence, allergies, anxiety and insomnia. Longitudinal studies suggest an association between anticholinergic exposure and risk of dementia. Prior studies often rely on crude exposure measures (use vs.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Background: The present study recapitulates the potency of the novel synthesized piperazine-benzoquinone derivative as a lead molecule selectively targeting AChE along with the antioxidative potential for the management of cognitive decline in Alzheimer's disease.
Method: Novel piperazine-benzoquinone derivative was synthesized implementing appropriate synthetic procedures and was characterized by various spectral and elemental techniques. The purity of this synthetic analogue was ascertained by TLC, melting point determination and elemental analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!